- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT00816400
A Dose Escalation, Dose Expansion Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-575, in Subjects With Advanced Tumors. (MEDI-575)
3 aprile 2018 aggiornato da: MedImmune LLC
A Phase 1, Multicenter, Open-label, Single-arm, Dose-escalation Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-575, a Fully Human Monoclonal Antibody Directed Against Platelet-derived Growth Factor Receptor Alpha (PDGFRα), in Subjects With Advanced Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy Exists
Evaluate the safety, tolerability and the tolerated maximum dose of MEDI-575 in adult subjects with advanced solid tumors refractory to standard therapy or for which no standard therapy exists.
Panoramica dello studio
Tipo di studio
Interventistico
Iscrizione (Effettivo)
49
Fase
- Fase 1
Contatti e Sedi
Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.
Luoghi di studio
-
-
Colorado
-
Denver, Colorado, Stati Uniti
- Research Site
-
-
Indiana
-
Indianapolis, Indiana, Stati Uniti
- Research Site
-
-
Nevada
-
Las Vegas, Nevada, Stati Uniti
- Research Site
-
-
Texas
-
Dallas, Texas, Stati Uniti
- Research Site
-
-
Virginia
-
Norfolk, Virginia, Stati Uniti
- Research Site
-
-
Criteri di partecipazione
I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.
Criteri di ammissibilità
Età idonea allo studio
18 anni e precedenti (Adulto, Adulto più anziano)
Accetta volontari sani
No
Sessi ammissibili allo studio
Tutto
Descrizione
Inclusion Criteria:
- Histologically confirmed advanced solid tumor for which no curative or standard therapies exist
- Karnofsky performance status of ≥ 60
- Life expectancy of >12 weeks
- Adequate hematologic and organ function
- Negative serum pregnancy test (women only)
- Two methods of birth control for female participants of child-bearing potential or male participants with their female partners of child-bearing potential
Exclusion Criteria:
- Prior chemotherapy or investigational treatment within 4 weeks of study drug administration
- Prior biological or immunological treatment within 6 weeks of study drug administration
- Concurrent therapy for of cancer
- Major surgery within four weeks or minor surgery within two weeks of study drug administration
- History of diabetes or current treatment for diabetes
- New York Heart Association ≥ Grade 2 congestive heart failure
- History of myocardial infarction, unstable angina, transient ischemic attack or stroke within the previous 6 months prior to study entry
- History of other invasive malignancy within 5 years (exceptions are cervical carcinoma in situ, non-melanomatous carcinoma of the skin or ductal carcinoma in situ of the breast that are surgically cured)
- Significant active infection
- Known brain metastases
- Pregnancy or lactation or plans to become pregnant while on study
- Clinically significant abnormality on ECG
Piano di studio
Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: MEDI-575, 3.0 mg/kg QWk Escalation Phase (Cohort 1)
Single lead-in dose of MEDI-575 at 0.5 mg/kg as a 60-minute intravenous (IV) infusion administered 7 days prior to first dose at 3.0 mg/kg; MEDI-575 administered at 3.0 mg/kg as a 60-minute IV infusion on Study Days 1, 8, and 15 (once every 7 days [QWk]) of each 21-day treatment cycle until unacceptable toxicity, documentation of disease progression, or other reasons for participant withdrawal occurred.
|
MEDI-575 as an IV infusion
|
Sperimentale: MEDI-575, 6.0 mg/kg QWk Escalation Phase (Cohort 2)
MEDI-575 administered at 6.0 mg/kg as a 60-minute IV infusion on Study Days 1, 8, and 15 (QWk) of each 21-day treatment cycle until unacceptable toxicity, documentation of disease progression, or other reasons for participant withdrawal occurred.
|
MEDI-575 as an IV infusion
|
Sperimentale: MEDI-575, 9.0 mg/kg QWk Escalation Phase (Cohort 3)
MEDI-575 administered at 9.0 mg/kg as a 60-minute IV infusion on Study Days 1, 8, and 15 (QWk) of each 21-day treatment cycle until unacceptable toxicity, documentation of disease progression, or other reasons for participant withdrawal occurred.
|
MEDI-575 as an IV infusion
|
Sperimentale: MEDI-575, 12 mg/kg QWk Escalation Phase (Cohort 4)
MEDI-575 administered at 12.0 mg/kg as a 60-minute IV infusion on Study Days 1, 8, and 15 (QWk) of each 21-day treatment cycle until unacceptable toxicity, documentation of disease progression, or other reasons for participant withdrawal occurred.
|
MEDI-575 as an IV infusion
|
Sperimentale: MEDI-575, 15 mg/kg QWk Escalation Phase (Cohort 5)
MEDI-575 administered at 15.0 mg/kg as a 60-minute IV infusion on Study Days 1, 8, and 15 (QWk) of each 21-day treatment cycle until unacceptable toxicity, documentation of disease progression, or other reasons for participant withdrawal occurred.
|
MEDI-575 as an IV infusion
|
Sperimentale: MEDI-575, 25 mg/kg Q3Wk Escalation Phase (Cohort 6)
MEDI-575 administered at 25.0 mg/kg as a 90-minute IV infusion on Study Day 1 of each 21-day treatment cycle (once every 21 days [Q3Wk]) until unacceptable toxicity, documentation of disease progression, or other reasons for participant withdrawal occurred.
|
MEDI-575 as an IV infusion
|
Sperimentale: MEDI-575, 35 mg/kg Q3Wk Escalation Phase (Cohort 7)
MEDI-575 administered at 35.0 mg/kg as a 90-minute IV infusion on Study Day 1 of each 21-day treatment cycle (Q3Wk) until unacceptable toxicity, documentation of disease progression, or other reasons for participant withdrawal occurred.
|
MEDI-575 as an IV infusion
|
Sperimentale: MEDI-575, 9.0 mg/kg QWk Expansion Phase
MEDI-575 administered at 9.0 mg/kg as a 60-minute IV infusion on Study Days 1, 8, and 15 (QWk) of each 21-day treatment cycle until unacceptable toxicity, documentation of disease progression, or other reasons for participant withdrawal occurred.
|
MEDI-575 as an IV infusion
|
Sperimentale: MEDI-575, 25 mg/kg Q3Wk Expansion Phase
MEDI-575 administered at 25.0 mg/kg as a 90-minute IV infusion on Study Day 1 of each 21-day treatment cycle (Q3Wk) until unacceptable toxicity, documentation of disease progression, or other reasons for participant withdrawal occurred.
|
MEDI-575 as an IV infusion
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Number of Participants With Adverse Events
Lasso di tempo: From the start of study drug administration through 30 days after last dose of MEDI-575, up to 112 weeks
|
An adverse event (AE) is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug.
Treatment-emergent AEs (TEAEs) are events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug, for the period extending to 30 days after the last dose of study drug.
Participants were counted only once for each event and by the highest event severity, regardless of how many events the participant experienced.
The AEs were summarized using Medical Dictionary for Regulatory Activities (MedDRA) version 14.1.
|
From the start of study drug administration through 30 days after last dose of MEDI-575, up to 112 weeks
|
Number of Participants With Serious Adverse Events
Lasso di tempo: From the start of study drug administration through 30 days after last dose of MEDI-575, up to 112 weeks
|
A serious AE (SAE) is any AE that results in death, is immediately life threatening, require (or prolong) inpatient hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly or birth defect, or is an important medical event that may jeopardize the participant or may require medical intervention to prevent one of the outcomes listed above.
Treatment-emergent SAEs that emerged after start of study drug were reported.
Participants were counted only once for each event and by the highest event severity, regardless of how many events the participant experienced.
The SAEs were summarized using MedDRA version 14.1.
|
From the start of study drug administration through 30 days after last dose of MEDI-575, up to 112 weeks
|
Treatment-emergent Adverse Events Related to Laboratory Parameters
Lasso di tempo: From the start of study drug administration through 30 days after last dose of MEDI-575, up to 112 weeks
|
Laboratory evaluations of blood and urine samples were performed, including hematology (complete blood count, differential, and platelet count); serum chemistry (SrChem) aspartate transaminase (AST), alanine transaminase, total bilirubin, creatinine, alkaline phosphatase, sodium, potassium, chloride, phosphorus, calcium, glucose, magnesium, albumin, and lactate dehydrogenase); and routine urinalysis.
Number of participants with TEAEs related to laboratory evaluations were reported.
|
From the start of study drug administration through 30 days after last dose of MEDI-575, up to 112 weeks
|
Treatment-emergent Adverse Events Related to Electrocardiogram Evaluations
Lasso di tempo: From the start of study drug administration through 30 days after last dose of MEDI-575, up to 112 weeks
|
All 12-lead electrocardiograms (ECGs) performed during the study were obtained in triplicate (ie, 3 ECGs were obtained within a 5-minute time interval) and analyzed.
ECG parameters included heart rate (high and low), QT interval, QTcB (corrected QT interval per Bazett's formula), and QTcF (corrected QT interval per Fridericia's formula).
Number of participants with TEAEs related to ECG after the start of study drug were reported.
|
From the start of study drug administration through 30 days after last dose of MEDI-575, up to 112 weeks
|
Treatment-emergent Adverse Events Related to Vital Sign Parameters
Lasso di tempo: From the start of study drug administration through 30 days after last dose of MEDI-575, up to 112 weeks
|
Vital signs (temperature, blood pressure, pulse rate, and respiratory rate) were performed throughout the study.
The TEAEs related to vital signs in participants were reported.
|
From the start of study drug administration through 30 days after last dose of MEDI-575, up to 112 weeks
|
Maximum Tolerated Dose (MTD)
Lasso di tempo: From the start of study drug administration through 30 days after last dose of MEDI-575, up to 112 weeks
|
For the dose escalation phase, a minimum of 21 evaluable participants (3 participants each in Dose Cohorts 1 through 7) were required for this study if Dose Limiting Toxicities (DLTs) do not occur.
If a DLT does occur among the first 3 participants in a cohort, 3 additional participants were to be added to the cohort; 3 more participants were to be added to a cohort to determine the MTD if only 3 participants have been previously treated at that dose.
The MTD is the maximum dose at which no more than 1 out of 6 participants experienced a DLT.
A DLT is defined as any grade 3 or higher hematologic toxicity or any grade 3 or higher non-hematologic toxicity except grade 3 fever (in the absence of neutropenia) or grade 3 rigors/chills.
|
From the start of study drug administration through 30 days after last dose of MEDI-575, up to 112 weeks
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Pharmacokinetics (PK) of MEDI-575 After the First Dose: Observed Maximum Serum Concentration (Cmax)
Lasso di tempo: For 0.5/3, 6, 9, 12, 15 mg/kg: Cycle 1: Day 1 (pre- and end of infusion, 2 and 6 hours post infusion), Days 2, 3 and 8 (pre-dose); For 25 and 35 mg/kg: Cycle 1: Day 1 (pre- and end of infusion, 2 and 6 hours post infusion), Days 2, 3, 8 and 15.
|
The concentration of MEDI-575 quantitatively determined in serum samples using a validated electrochemiluminescence (ECL) PK assay.
The Cmax after the first dose was obtained directly from the measured concentration-time curves.
The concentration-time curve is the result of blood sampling at specified time points and its measured concentration of MEDI-575.
|
For 0.5/3, 6, 9, 12, 15 mg/kg: Cycle 1: Day 1 (pre- and end of infusion, 2 and 6 hours post infusion), Days 2, 3 and 8 (pre-dose); For 25 and 35 mg/kg: Cycle 1: Day 1 (pre- and end of infusion, 2 and 6 hours post infusion), Days 2, 3, 8 and 15.
|
PK of MEDI-575 After the First Dose: Time to Maximum Concentration (Tmax)
Lasso di tempo: For 0.5/3, 6, 9, 12, 15 mg/kg: Cycle 1: Day 1 (pre- and end of infusion, 2 and 6 hours post infusion), Days 2, 3 and 8 (pre-dose); For 25 and 35 mg/kg: Cycle 1: Day 1 (pre- and end of infusion, 2 and 6 hours post infusion), Days 2, 3, 8 and 15.
|
The time to reach maximum serum concentration after the first dose of MEDI-575 was obtained directly from the measured concentration-time curves.
The concentration-time curve is the result of blood sampling at specified time points and its measured concentration of MEDI-575.
|
For 0.5/3, 6, 9, 12, 15 mg/kg: Cycle 1: Day 1 (pre- and end of infusion, 2 and 6 hours post infusion), Days 2, 3 and 8 (pre-dose); For 25 and 35 mg/kg: Cycle 1: Day 1 (pre- and end of infusion, 2 and 6 hours post infusion), Days 2, 3, 8 and 15.
|
PK of MEDI-575 After the First Dose: Dose-normalized Maximum Serum Concentration (Cmax/Dose)
Lasso di tempo: For 0.5/3, 6, 9, 12, 15 mg/kg: Cycle 1: Day 1 (pre- and end of infusion, 2 and 6 hours post infusion), Days 2, 3 and 8 (pre-dose); For 25 and 35 mg/kg: Cycle 1: Day 1 (pre- and end of infusion, 2 and 6 hours post infusion), Days 2, 3, 8 and 15.
|
The Cmax/dose after the first dose of MEDI-575 was obtained directly from the measured concentration-time curves.
The concentration-time curve is the result of blood sampling at specified time points and its measured concentration of MEDI-575.
|
For 0.5/3, 6, 9, 12, 15 mg/kg: Cycle 1: Day 1 (pre- and end of infusion, 2 and 6 hours post infusion), Days 2, 3 and 8 (pre-dose); For 25 and 35 mg/kg: Cycle 1: Day 1 (pre- and end of infusion, 2 and 6 hours post infusion), Days 2, 3, 8 and 15.
|
PK of MEDI-575 After the First Dose: Trough Serum Concentration (Ctrough)
Lasso di tempo: For 0.5/3, 6, 9, 12, 15 mg/kg: Cycle 1: Day 1 (pre- and end of infusion, 2 and 6 hours post infusion), Days 2, 3 and 8 (pre-dose); For 25 and 35 mg/kg: Cycle 1: Day 1 (pre- and end of infusion, 2 and 6 hours post infusion), Days 2, 3, 8 and 15.
|
The Ctrough ie, measured concentration at the end of a dosing interval (taken directly before next dose administration) of MEDI-575 was obtained directly from the measured concentration-time curves.
The concentration-time curve is the result of blood sampling at specified time points and its measured concentration of MEDI-575.
|
For 0.5/3, 6, 9, 12, 15 mg/kg: Cycle 1: Day 1 (pre- and end of infusion, 2 and 6 hours post infusion), Days 2, 3 and 8 (pre-dose); For 25 and 35 mg/kg: Cycle 1: Day 1 (pre- and end of infusion, 2 and 6 hours post infusion), Days 2, 3, 8 and 15.
|
PK of MEDI-575 After the First Dose: Area Under the Serum Concentration-time Curve Over the Dosing Interval (AUCτ)
Lasso di tempo: For 0.5/3, 6, 9, 12, 15 mg/kg: Cycle 1: Day 1 (pre- and end of infusion, 2 and 6 hours post infusion), Days 2, 3 and 8 (pre-dose); For 25 and 35 mg/kg: Cycle 1: Day 1 (pre- and end of infusion, 2 and 6 hours post infusion), Days 2, 3, 8 and 15.
|
The AUCτ was obtained directly from the measured concentration-time curves.
The concentration-time curve is the result of blood sampling at specified time points and its measured concentration of MEDI-575.
|
For 0.5/3, 6, 9, 12, 15 mg/kg: Cycle 1: Day 1 (pre- and end of infusion, 2 and 6 hours post infusion), Days 2, 3 and 8 (pre-dose); For 25 and 35 mg/kg: Cycle 1: Day 1 (pre- and end of infusion, 2 and 6 hours post infusion), Days 2, 3, 8 and 15.
|
PK of MEDI-575 After the First Dose: Dose-normalized Area Under the Serum Concentration-time Curve (AUCτ/Dose)
Lasso di tempo: For 0.5/3, 6, 9, 12, 15 mg/kg: Cycle 1: Day 1 (pre- and end of infusion, 2 and 6 hours post infusion), Days 2, 3 and 8 (pre-dose); For 25 and 35 mg/kg: Cycle 1: Day 1 (pre- and end of infusion, 2 and 6 hours post infusion), Days 2, 3, 8 and 15.
|
The AUCτ/dose was obtained directly from the measured concentration-time curves.
The concentration-time curve is the result of blood sampling at specified time points and its measured concentration of MEDI-575.
|
For 0.5/3, 6, 9, 12, 15 mg/kg: Cycle 1: Day 1 (pre- and end of infusion, 2 and 6 hours post infusion), Days 2, 3 and 8 (pre-dose); For 25 and 35 mg/kg: Cycle 1: Day 1 (pre- and end of infusion, 2 and 6 hours post infusion), Days 2, 3, 8 and 15.
|
Number of Participants Positive for Anti-drug Antibodies Formation for MEDI-575 at Any Visit
Lasso di tempo: Preinfusion on Cycle 1 Day 1 and 30 days after the last dose, up to 112 weeks
|
Blood samples for immunogenicity assessments were collected from participants prior to the initiation of infusion of each treatment cycle of MEDI-575.
Anti-MEDI-575 antibodies were analyzed using the electro-chemiluminescence (ECL) based method.
Only the number of participants positive for anti-MEDI-575 antibodies at any visit are presented.
|
Preinfusion on Cycle 1 Day 1 and 30 days after the last dose, up to 112 weeks
|
Percentage of Participants With Objective Response
Lasso di tempo: From study entry through the end of the study, up to 34 months
|
Objective response rate is defined as the proportion of participants with confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) guidelines.
Confirmed responses are those that persist on repeat imaging study at least 4 weeks after the initial documentation of response.
The CR is defined as disappearance of all target and non-target lesions, and normalization of tumor marker level.
The PR is defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD.
|
From study entry through the end of the study, up to 34 months
|
Time to Response
|
Time to response was measured from the start of treatment with MEDI-575 to the first documentation of objective response (confirmed CR or PR).
The time to response is assessed only for the participants who have achieved the objective response.
|
|
Duration of Response
|
Duration of response is defined as the duration from the first documentation of objective response to the first documented disease progression.
Disease progression is defined according to RECIST guidelines (ie, at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions).
The duration of response was censored on the date of last tumor assessment documenting absence of disease progression for participants who have no documented progression prior to data cutoff, dropout, or the initiation of alternate anticancer treatment.
Duration of response was calculated for the subgroup of participants with an objective response.
|
|
Time to Progression
Lasso di tempo: Start of treatment with MEDI-575 until the documentation of disease progression, up to 24 months
|
Time to progression (TTP) is defined as time from the start of treatment with MEDI-575 until the documentation of disease progression.
Disease progression is defined according to RECIST guidelines (ie, at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions).
The TTP was censored on the date of last tumor assessment documenting absence of tumor progression for participants who have no documented progression prior to data cutoff, dropout, or the initiation of alternate anticancer treatment.
TTP was censored on the first date of treatment for the participants with no tumor assessments after the start of MEDI-575 treatment.
|
Start of treatment with MEDI-575 until the documentation of disease progression, up to 24 months
|
Progression-free Survival
Lasso di tempo: Start of treatment with MEDI-575 until the documentation of disease progression or death due to any cause whichever occurs first, up to 24 months
|
Progression-free survival (PFS) is defined as time from the start of treatment with MEDI-575 until the documentation of disease progression or death due to any cause, whichever occurred first.
Disease progression is defined according to RECIST guidelines (ie, at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions).
PFS was censored on the date of last tumor assessment documenting absence of tumor progression for participants who have no documented progression and were still alive prior to data cutoff, dropout, or the initiation of alternate anticancer treatment.
PFS was censored on the first date of treatment for the participants with no tumor assessments after the start of MEDI-575 treatment.
|
Start of treatment with MEDI-575 until the documentation of disease progression or death due to any cause whichever occurs first, up to 24 months
|
Overall Survival
Lasso di tempo: From the start of treatment with MEDI-575 until death or end of study, up to 33 months
|
Overall survival (OS) is defined as the time from the start of treatment with MEDI-575 until death.
For the participants who were alive at the end of study or lost to follow-up, OS was censored on the last date when participants were known to be alive.
|
From the start of treatment with MEDI-575 until death or end of study, up to 33 months
|
Collaboratori e investigatori
Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.
Sponsor
Pubblicazioni e link utili
La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.
Studiare le date dei record
Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.
Studia le date principali
Inizio studio (Effettivo)
2 marzo 2009
Completamento primario (Effettivo)
19 gennaio 2012
Completamento dello studio (Effettivo)
19 gennaio 2012
Date di iscrizione allo studio
Primo inviato
23 dicembre 2008
Primo inviato che soddisfa i criteri di controllo qualità
30 dicembre 2008
Primo Inserito (Stima)
1 gennaio 2009
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
26 giugno 2018
Ultimo aggiornamento inviato che soddisfa i criteri QC
3 aprile 2018
Ultimo verificato
1 aprile 2018
Maggiori informazioni
Termini relativi a questo studio
Altri numeri di identificazione dello studio
- MI-CP187
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Cancro
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletatoAdenocarcinoma dell'intestino tenue | Adenocarcinoma dell'intestino tenue in stadio III AJCC v8 | Adenocarcinoma dell'intestino tenue in stadio IIIA AJCC v8 | Adenocarcinoma dell'intestino tenue in stadio IIIB AJCC v8 | Adenocarcinoma dell'intestino tenue stadio IV AJCC v8 | Ampolla di Vater... e altre condizioniStati Uniti
-
Georgetown UniversityNational Cancer Institute (NCI); American Cancer Society, Inc.; Susan G. Komen...CompletatoStudio delle donne cinesi che non hanno aderito alle linee guida per lo screening mammografico dell'American Cancer SocietyStati Uniti
-
National Cancer Institute (NCI)ReclutamentoKita-kyushu Lung Cancer Antigen 1, umanoStati Uniti
-
Novartis PharmaceuticalsReclutamentoEGFR mutante avanzato Non SmallSellLung Cancer (NSCLC), KRAS G12-mutant NSCLC, Esophageal SquamousCell Cancer (SCC), Head/Neck SCC, MelanomaOlanda, Corea, Repubblica di, Spagna, Taiwan, Giappone, Italia, Canada, Stati Uniti, Singapore
-
Emory UniversityNational Cancer Institute (NCI)RitiratoCancro al seno in stadio IV prognostico AJCC v8 | Neoplasia maligna metastatica nel cervello | Carcinoma mammario metastatico | Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8
-
NRG OncologyNational Cancer Institute (NCI)Attivo, non reclutanteCancro al seno in stadio anatomico IV AJCC v8 | Cancro al seno in stadio IV prognostico AJCC v8 | Neoplasia maligna metastatica nell'osso | Neoplasia maligna metastatica nei linfonodi | Neoplasia maligna metastatica nel fegato | Carcinoma mammario metastatico | Neoplasia maligna metastatica nel... e altre condizioniStati Uniti, Canada, Arabia Saudita, Corea, Repubblica di
-
Jonsson Comprehensive Cancer CenterNon ancora reclutamentoCarcinoma della prostata | Stadio IVB Cancro alla prostata American Joint Committee on Cancer (AJCC) v8Stati Uniti
-
Rashmi Verma, MDNational Cancer Institute (NCI)ReclutamentoCarcinoma prostatico resistente alla castrazione | Adenocarcinoma prostatico metastatico | Stadio IVB Cancro alla prostata American Joint Committee on Cancer (AJCC) v8Stati Uniti
-
Assiut UniversityNon ancora reclutamentoDeterminare l’incidenza cumulativa di AKI utilizzando i criteri KDIGO in pazienti pediatrici con tumori maligni presso il South Egypt Cancer Institute (SECI)
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)Attivo, non reclutanteStadio III Adenocarcinoma della prostata AJCC v7 | Stadio II Adenocarcinoma prostatico AJCC v7 | Fase I Adenocarcinoma della prostata American Joint Committee on Cancer (AJCC) v7Stati Uniti
Prove cliniche su MEDI-575
-
MedImmune LLCCompletatoGlioblastoma multiformeStati Uniti
-
AstraZenecaMedImmune LLCCompletato
-
BioCryst PharmaceuticalsAttivo, non reclutanteAngioedema ereditario | HAEFrancia, Macedonia del Nord, Polonia, Corea, Repubblica di, Slovacchia, Sud Africa, Cechia
-
MedImmune LLCTerminatoCarcinoma polmonare non a piccole celluleStati Uniti, Canada, Giappone, Polonia, Germania, Ungheria, Francia
-
MedImmune LLCCompletato
-
MedImmune LLCCompletatoCancro | Malattia del trapianto contro l'ospiteStati Uniti
-
MedImmune LLCTerminatoLinfoma | Leucemia | CancroStati Uniti
-
MedImmune LLCCompletatoSclerosi multipla, forme recidivantiStati Uniti, Spagna, Polonia, Ucraina
-
MedImmune LLCCompletatoLupus Eritematoso, SistemicoStati Uniti, Corea, Repubblica di, Messico, Perù, Ungheria, Ucraina, Cechia, Bulgaria, Colombia, Brasile, Polonia, Romania, Taiwan
-
Sidney Kimmel Comprehensive Cancer Center at Johns...TerminatoMieloma multiploStati Uniti